Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
Referencias
Additional references
American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins‐Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstetrics and Gynecology 2009;113(4):957‐66.
Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD007697.pub2]
Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. Journal of Clinical Oncology 2004;22(6):1045‐54.
Arts‐de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. European Journal of Cancer 2016;61:137‐45. [PUBMED: 27209246]
Barlin J, Pike M, Otegbeye E, Arnold A, Stadler Z, Robson M, et al. Abstract no 245: Does postmenopausal risk‐reducing salpingo‐oophorectomy reduce the risk of BRCA‐associated breast cancer? Proceedings of the 2013 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer; 2013 March 9‐12; Los Angeles (CA). 2013.
Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, et al. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Ecancermedicalscience 2016;10:639. [PUBMED: 27350785]
Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk‐reducing salpingo‐oophorectomy: a retrospective study and review. BMC Cancer 2016;16:18. [PUBMED: 26768420]
Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunction after risk‐reducing salpingo‐oophorectomy: effects of a brief, psychosexual intervention. Journal of Sexual Medicine 2015;12(1):189‐97. [PUBMED: 25311333]
Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA‐positive women undergoing surgery for ovarian cancer risk reduction. Journal of Clinical Oncology 2007;25(25):3985‐90. [PUBMED: 17761984]
Chan RJ, Webster J, Marquart L. Information interventions for orienting patients and their carers to cancer care facilities. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD008273.pub2]
Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Current Opinion in Obstetrics & Gynecology 2007;19(1):3‐9. [PUBMED: 17218844]
National Institutes of Health ‐ National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_8.5x11.pdf (accessed 05 December 2016).
De Felice F, Marchetti C, Musella A, Palaia I, Perniola G, Musio D, et al. Bilateral risk‐reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta‐analysis. Annals of Surgical Oncology 2015;22(9):2876‐80. [PUBMED: 25808098]
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. Systematic Reviews in Health Care: Meta‐Analysis in Context. London: BMJ Publication Group, 2001.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk‐reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967‐75. [PUBMED: 20810374]
Eccles DM, Balmaña J, Clune J, Ehlken B, Gohlke A, Hirst C, et al. Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review. Advances in Therapy 2016;33(2):129‐50. [PUBMED: 26809252]
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez‐Martin A, Colombo N, Sessa C: ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2013;24(S6):vi24‐32.
Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, et al. Bone mineral density and fractures after risk‐reducing salpingo‐oophorectomy in women at increased risk for breast and ovarian cancer. European Journal of Cancer 2015;51(3):400‐8. [PUBMED: 25532426]
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo‐oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296(2):185‐92. [PUBMED: 16835424]
Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology 2014;32(15):1547‐53. [PUBMED: 24567435]
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics 1998;62(3):676‐89.
Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, et al. BRCA‐associated ovarian cancer: from molecular genetics to risk management. BioMed Research International 2014;2014:787143. [PUBMED: 25136623]
Gottschau M, Mellemkjaer L, Hannibal CG, Kjaer SK. Ovarian and tubal cancer in Denmark: an update on incidence and survival. Acta Obstetricia et Gynecologica Scandinavica 2016;95(10):1181‐9. [PUBMED: 27454324]
GRADE Working Group, McMaster University, Hamilton (ON). GRADEpro Guideline Development Tool (GDT). GRADE Working Group, McMaster University, Hamilton (ON), 2014.
Guidozzi F. Hormone therapy after prophylactic risk‐reducing bilateral salpingo‐oophorectomy in women who have BRCA gene mutation. Climacteric 2016;19(5):419‐22. [PUBMED: 27426853]
Harmsen MG, Arts‐de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk‐reducing salpingo‐oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non‐randomised multicentre study. BMC Cancer 2015;15:593. [PUBMED: 26286255]
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. American Journal of Human Genetics 1999;64(4):963‐70. [PUBMED: 10090881]
Hartmann LC, Degnim AC, Dupont WD. Atypical hyperplasia of the breast. New England Journal of Medicine 2015;372(13):1271‐2. [PUBMED: 25806929]
Hartmann LC, Lindor NM. Risk‐reducing surgery in hereditary breast and ovarian cancer. New England Journal of Medicine 2016;374(24):2404. [PUBMED: 27305204]
Heemskerk‐Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, et al. Breast cancer risk after salpingo‐oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Journal of the National Cancer Institute 2015;107(5):pii: djv033. [PUBMED: 25788320]
Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow‐up study. British Journal of Cancer 2007;96(9):1335‐42. [PUBMED: 17426707]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, and Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed 05 December 2016).
Iavazzo C, Gkegkes ID, Vrachnis N. Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo‐oophorectomy. Journal of the Turkish German Gynecological Association 2016;17(2):73‐6. [PUBMED: 27403072]
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta‐analysis. European Journal of Cancer 2010;46(12):2275‐84. [PUBMED: 20537530]
Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S. Ovarian cancer and BRCA1/2 testing: opportunities to improve clinical care and disease prevention. Frontiers in Oncology 2016;6:119. [PUBMED: 27242959]
Karlan BY. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecologic Oncology 2004;92(2):519‐20.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk‐reducing salpingo‐oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine 2002;346(21):1609‐15. [PUBMED: 12023992]
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk‐reducing salpingo‐oophorectomy for the prevention of BRCA1‐ and BRCA2‐associated breast and gynecologic cancer: a multicenter, prospective study. Journal of Clinical Oncology 2008;26(8):1331‐7. [PUBMED: 18268356]
King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302(5645):643‐6.
Koc N, Ayas S, Arinkan SA. Comparison of the classical method and SEE‐FIM protocol in detecting microscopic lesions in fallopian tubes with gynecological lesions. Journal of Pathology and Translational Medicine 2016 Aug 19 [Epub ahead of print]. [DOI: 10.4132/jptm.2016.06.17; PUBMED: 27539290]
Kramer L. Mixed reviews on removing fallopian tubes to prevent ovarian cancer. Canadian Medical Association Journal 2013 June 11;185(9):E391‐2.
Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schünemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;2:81.
Leath CA, Huh WK, Alvarez RD. Drawing the line in risk‐reducing gynecologic surgery in women with a BRCA mutation. JAMA Oncology 2016;2(11):1409‐11. [PUBMED: 27367041]
Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecologic Oncology 2013;129(1):120‐3. [PUBMED: 23237768]
Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC. p53 signature and serous tubal in‐situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. International Journal of Gynecological Pathology 2011;30(5):417‐24. [PUBMED: 21804388]
Lheureux S, Karakasis K, Harter P, Scott C, Bacon M, Bryce J, et al. Germline BRCA1/2 testing practices in ovarian cancer: current state and opportunities for new directions. Gynecologic Oncology 2016;140(1):90‐4. [PUBMED: 26475959]
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 2009;339:b2700.
Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD002748.pub3]
Lynch HT, Snyder C, Casey MJ. Hereditary ovarian and breast cancer: what have we learned?. Annals of Oncology 2013;24(Suppl 8):viii83‐viii95.
Maeshima Y, Oseto K, Katsuragi R, Yoshimoto Y, Takahara S, Yamauchi A. Experience with bilateral risk‐reducing mastectomy for an unaffected BRCA mutation carrier. Journal of Breast Cancer 2016;19(2):218‐21. [PUBMED: 27382401]
Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE‐FIM) protocol?. International Journal of Gynecological Pathology 2013;32(4):353‐7. [PUBMED: 23722507]
Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, et al. Cost‐effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history‐based testing. Journal of the National Cancer Institute 2015;107(1):380. [PUBMED: 25435542]
Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi‐Jewish community: a randomized controlled trial. Journal of the National Cancer Institute 2015;107(1):379. [PUBMED: 25435541]
Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk‐reducing salpingo‐oophorectomy: a meta‐analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Women's Health 2014;14:150. [PUBMED: 25494812]
McGuire V, Hartge P, Liao LM, Sinha R, Bernstein L, Canchola AJ, et al. Parity and oral contraceptive use in relation to ovarian cancer risk in older women. Cancer Epidemiology, Biomarkers & Prevention 2016;25(7):1059‐63. [PUBMED: 27197274]
Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
Meaney‐Delman D, Bellcross CA. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynaecologists. Obstetrics and Gynecology Clinics of North America 2013;40(3):475‐512.
Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim‐Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncology 2015;1(3):306‐13. [PUBMED: 26181175]
Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutation Research 2003;544(1):9‐41. [PUBMED: 12888106]
Narod SA. Hormonal prevention of hereditary breast cancer. Annals of the New York Academy of Sciences 2001;952:36‐43. [PUBMED: 11795442]
National Comprehensive Cancer Network. Epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) Version 3.2014. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (accessed 05 December 2016).
Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow‐up. British Journal of Cancer 2004;90(8):1492‐7. [PUBMED: 15083174]
Ozols RF. Challenges for chemotherapy in ovarian cancer. Annals of Oncology 2006;17(Suppl 5):v181‐7.
Pal T, Permuth‐Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104(12):2807‐16. [PUBMED: 16284991]
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early‐onset breast cancer. Journal of the National Cancer Institute 1999;91(11):943‐9. [PUBMED: 10359546]
Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. International Journal of Cancer 2013;132(9):2127‐33.
Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al. Risk‐reducing salpingo‐oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. Journal of Clinical Oncology 2005;23(1):127‐32.
Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk‐reducing salpingo‐oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical‐pathological protocol. International Journal of Gynecological Cancer 2011;21(5):846‐51. [PUBMED: 21670699]
Powell CB. Risk reducing salpingo‐oophorectomy for BRCA mutation carriers: twenty years later. Gynecologic Oncology 2014;132(2):261‐3. [PUBMED: 24528542]
Ready K, Gutierrez‐Barrera AM, Amos C, Meric‐Bernstam F, Lu K, Hortobagyi G, et al. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast Journal 2011;17(2):210‐2. [PUBMED: 21294809]
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine 2002;346(21):1616‐22.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al: PROSE Study Group. Effect of short‐term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Journal of Clinical Oncology 2005;23(31):7804‐10.
Rebbeck TR, Kauff ND, Domchek SM. Meta‐analysis of risk reduction estimates associated with risk‐reducing salpingo‐oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute 2009;101(2):80‐7. [PUBMED: 19141781]
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 2001;68(3):700‐10. [PUBMED: 11179017]
Roila F, Cortesi E. Quality of life as a primary end point in oncology. Annals of Oncology 2001;12 Suppl 3:S3‐6. [PUBMED: 11804381]
Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. Journal of Clinical Oncology 2013;31(1):49‐57. [PUBMED: 23213100]
Rosenthal AN, Fraser L, Philpott S, Manchanda R, Badman P, Hadwin R, et al. Final results of 4‐monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2). 2013 ASCO Annual Meeting. Journal of Clinical Oncology 2013;(Suppl):Abstract 5507.
Salhab M, Bismohun S, Mokbel K. Risk‐reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Women's Health 2010;10:28. [PUBMED: 20961453]
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clinical Cancer Research 2002;8(12):3776‐81.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecologic Oncology 2013;130(1):127‐31. [PUBMED: 23562522]
Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk‐reducing salpingo‐oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncology 2016;2(11):1434‐40. [PUBMED: 27367496]
Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL‐index for use by physicians. Journal of Chronic Diseases 1981;34(12):585‐97. [PUBMED: 7309824]
Staples J, Goodman A. Chapter 14: PARP inhibitors in ovarian cancer. In: Díaz‐Padilla I editor(s). Ovarian Cancer ‐ A Clinical and Translational Update. InTech, 2013.
Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. Journal of Clinical Oncology 2005;23(24):5588‐96. [PUBMED: 16110018]
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 1997;336(20):1401‐8.
Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends in Molecular Medicine 2002;8(12):571‐6. [PUBMED: 12470990]
van Verschuer VM, Heemskerk‐Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus‐Linthorst MM, Verhoef C, et al. Lower mitotic activity in BRCA1/2‐associated primary breast cancers occurring after risk‐reducing salpingo‐oophorectomy. Cancer Biology & Therapy 2014;15(4):371‐9. [PUBMED: 24423863]
Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 2014;343(6178):1470‐5. [PUBMED: 24675954]
Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. Familial breast cancer: characteristics and outcome of BRCA 1‐2 positive and negative cases. BMC Cancer 2005;5:70. [PUBMED: 15996267]
Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015;121(13):2108‐20. [PUBMED: 25820366]
